Literature DB >> 30478671

Severely bothersome fatigue in children and adolescents with cancer and hematopoietic stem cell transplant recipients.

Deborah Tomlinson1, Christina Baggott2, David Dix3, Paul Gibson4, Shannon Hyslop1, Donna L Johnston5, Andrea Orsey6, Carol Portwine7, Victoria Price8, Magimairajan Vanan9, Susan Kuczynski10, Brenda Spiegler11, George A Tomlinson12, L Lee Dupuis1,13,14, Lillian Sung15,16.   

Abstract

BACKGROUND: Objectives were to describe bothersome fatigue in children with cancer and hematopoietic stem cell (HSCT) recipients and to identify factors associated with severely bothersome fatigue.
METHODS: We included children ages 8-18 years treated for cancer or HSCT recipients from three groups: [1] receiving active cancer treatment and admitted to hospital for at least 3 days, [2] attending outpatient clinic for acute lymphoblastic leukemia maintenance therapy, and [3] attending outpatient clinic following treatment completion. Fatigue was measured using the Symptom Screening in Pediatrics Tool (SSPedi); severely bothersome fatigue was defined as a lot or extremely bothersome fatigue (score of 3-4 on 0-4 scale). Factors associated with severely bothersome fatigue were examined using univariate and multiple logistic regression.
RESULTS: Of 502 children included, 414 (82.5%) reported some degree of bothersome fatigue (scores 1-4), and 123 (24.5%) reported severely bothersome fatigue (score 3 or 4). In multiple regression analysis, factors significantly associated with severely bothersome fatigue were child age 11-14 and 15-18 years vs 8-10 years (odds ratio (OR) 2.11, 95% confidence interval (CI) 1.21-3.77 and OR 2.96, 95% CI 1.66-5.44), and inpatients receiving cancer treatment vs outpatients who had completed therapy (OR 3.85, 95% CI 2.17-7.27).
CONCLUSIONS: We found that 82.5% of children with cancer or HSCT recipients reported bothersome fatigue and 24.5% of children reported severely bothersome fatigue. Risk factors for severely bothersome fatigue were older age and inpatients receiving active cancer treatment. Future work should evaluate systematic symptom screening in clinical practice and apply interventions to reduce fatigue.

Entities:  

Keywords:  Adolescents; Children; Fatigue; Hematopoietic stem cell transplantation; Oncology

Mesh:

Year:  2018        PMID: 30478671     DOI: 10.1007/s00520-018-4555-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  5 in total

Review 1.  The Symptom Experience in Pediatric Cancer: Current Conceptualizations and Future Directions.

Authors:  Lindsay A Jibb; Suzanne Ameringer; Catherine Fiona Macpherson; Surabhi Sivaratnam
Journal:  Curr Oncol Rep       Date:  2022-02-12       Impact factor: 5.075

Review 2.  Body composition after allogeneic haematopoietic cell transplantation/total body irradiation in children and young people: a restricted systematic review.

Authors:  Ava Lorenc; Julian Hamilton-Shield; Rachel Perry; Michael Stevens
Journal:  J Cancer Surviv       Date:  2020-07-18       Impact factor: 4.442

3.  Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.

Authors:  Rajaram Nagarajan; Robert Gerbing; Todd Alonzo; Donna L Johnston; Richard Aplenc; Edward A Kolb; Soheil Meshinchi; Lamia P Barakat; Lillian Sung
Journal:  Cancer Med       Date:  2019-06-12       Impact factor: 4.452

Review 4.  Mindfulness Practices for Children and Adolescents Receiving Cancer Therapies.

Authors:  Shelley Murphy; Ani Jamyang Donma; Sara Ahola Kohut; Elli Weisbaum; Jacqueline H Chan; Erin Plenert; Deborah Tomlinson
Journal:  J Pediatr Hematol Oncol Nurs       Date:  2022 Jan-Feb

5.  Using the MDASI-Adolescent for Early Symptom Identification and Mitigation of Symptom Impact on Daily Living in Adolescent and Young Adult Stem Cell Transplant Patients.

Authors:  Irtiza N Sheikh; Jeffrey Miller; Basirat Shoberu; Clark R Andersen; Jian Wang; Loretta A Williams; Kris M Mahadeo; Rhonda Robert
Journal:  Children (Basel)       Date:  2021-12-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.